Arrayit Corporation (OTC: ARYC), a developer, manufacturer and marketer of proprietary life sciences technologies and consumables for disease prevention, treatment and cure, expects to benefit from President Obama’s Affordable Care Act (ACA). According to Forbes, ACA will lead to greater demand for medical tests. This is because under the new legislation, patients and corporations will not have to pay anything for these tests, while physicians will be reimbursed for providing these tests. This augurs well for Arrayit, which has a pipeline of preventive tests such as OvaDx® ovarian cancer test and the PDx™ Parkinson’s Disease test. Under ACA, OvaDx and PDx will not apply to patient’s deductible insurance bill. ARYC believes that these will further drive sales of its pre-symptomatic tests.
To read more about ARYC and subscribe to a monthly update, CEO interview etc, please click here – http://www.listonstreetpulse.com/tag/ARYC/
About Arrayit Corporation
Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company’s innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit’s products are used by every major research center in the world.
About Liston Street Pulse
Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Over the years, Liston Street Pulse’s original and unbiased analysis has helped the investor community immensely.
